Pharmalot Archives

Pharmalot Ed Silverman

Zantac lawsuits are tossed out as judge lambasts lack of evidence showing links to cancer

Pharmalot Ed Silverman

The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $805 million in 2021

Pharmalot Ed Silverman

France’s drug regulator is under investigation for its handling of a thyroid drug

Pharmalot Ed Silverman

U.S. delays backing for patent waivers on Covid-19 therapies and diagnostics

Pharmalot Ed Silverman

Pharmalittle: FDA fast tracks OTC version of Narcan; Express Scripts to keep Humira on its formulary but add biosimilars

Pharmalot Ed Silverman

Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug

Pharmalot Ed Silverman

‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Pharmalot Ed Silverman

Pharmalittle: Second clinical trial death may be linked to Eisai-Biogen Alzheimer’s drug; pharma presses the U.K. over ‘out of control’ levy

Pharmalot Andrew Joseph

Pharmalittle: FDA approves first gene therapy for hemophilia B; pharma’s reputation slips in U.S.

Pharmalot Damian Garde

Pharmalittle: GSK pulls a key blood-cancer drug off the market; Teva picks a new CEO

Pharmalot Ed Silverman

Pharmalittle: Type 1 diabetes drug is priced at $194,000; abortion opponents sue FDA over abortion pill approval

Pharmalot Ed Silverman

Sales of antibiotics for food-producing animals dropped by nearly half in Europe over the past decade

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

Pharmalot Ed Silverman

Pharmalittle: Big PBM keeps AbbVie’s Humira on formulary; Lilly CEO says fake tweet means there’s more to do on insulin costs

Pharmalot Ed Silverman

Lilly CEO concedes Twitter flap over insulin costs shows there’s ‘more work to do’

Pharmalot Ed Silverman

Pharmalittle: WHO scientist resigns amid shake-up; FDA considers over-the-counter naloxone

Pharmalot Ed Silverman

Walmart agrees to pay $3.1 billion in latest settlement stemming from the opioid crisis

Pharmalot Ed Silverman

Pharmalittle: Walmart to pay $3.1 billion to settle opioid claims; Indian Covid vaccine underwent troubling approval process

Pharmalot Ed Silverman

Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug

Pharmalot Ed Silverman

More drugmakers are expanding access in poorer countries, but progress continues to lag overall

Pharmalot Ed Silverman

‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process

Pharmalot Ed Silverman

Pharmalittle: Roche Alzheimer’s drug fails in two studies; Indivior bets on addiction market with deal to buy Opiant

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalot

Most Read

A year after petition, NIH will finally review request to lower cancer drug’s cost by sidestepping patents

Pharmalittle: J&J drops out of bidding for Horizon; FDA takes a harder line on fast-track approvals

Up and down the ladder: The latest comings and goings

Pharmalittle: Private equity moving to buy clinical trials firms; data provider limits media access to drug prices

Gilead wins a key battle with the CDC over patents for its Truvada HIV pill

Pharmalittle: Roche Alzheimer’s drug didn’t clear enough amyloid; startup to seek approval of nasal swab version of naloxone

Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information

Pharmalittle: Detailed data on Alzheimer’s drug hold up to scrutiny; Horizon in takeover talks with three pharma giants

All Coverage

Zantac lawsuits are tossed out as judge lambasts lack of evidence showing links to cancer

The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $805 million in 2021

France’s drug regulator is under investigation for its handling of a thyroid drug

U.S. delays backing for patent waivers on Covid-19 therapies and diagnostics

Pharmalittle: FDA fast tracks OTC version of Narcan; Express Scripts to keep Humira on its formulary but add biosimilars

Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug

‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Pharmalittle: Second clinical trial death may be linked to Eisai-Biogen Alzheimer’s drug; pharma presses the U.K. over ‘out of control’ levy

Pharmalittle: FDA approves first gene therapy for hemophilia B; pharma’s reputation slips in U.S.

Pharmalittle: GSK pulls a key blood-cancer drug off the market; Teva picks a new CEO

Pharmalittle: Type 1 diabetes drug is priced at $194,000; abortion opponents sue FDA over abortion pill approval

Sales of antibiotics for food-producing animals dropped by nearly half in Europe over the past decade

Up and down the ladder: The latest comings and goings

Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

Pharmalittle: Big PBM keeps AbbVie’s Humira on formulary; Lilly CEO says fake tweet means there’s more to do on insulin costs

Lilly CEO concedes Twitter flap over insulin costs shows there’s ‘more work to do’

Pharmalittle: WHO scientist resigns amid shake-up; FDA considers over-the-counter naloxone

Walmart agrees to pay $3.1 billion in latest settlement stemming from the opioid crisis

Pharmalittle: Walmart to pay $3.1 billion to settle opioid claims; Indian Covid vaccine underwent troubling approval process

Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug

More drugmakers are expanding access in poorer countries, but progress continues to lag overall

‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process

Pharmalittle: Roche Alzheimer’s drug fails in two studies; Indivior bets on addiction market with deal to buy Opiant

Up and down the ladder: The latest comings and goings

Pharmalittle: Lilly says fake Twitter account offered free insulin; AstraZeneca drops plans for Covid shot in the U.S.

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day